Lecanemab was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.
The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry.
The award for Best New Drug recognizes excellence in pharmaceutical development and celebrates lecanemab as the first and only treatment approved in Japan and the United States shown to reduce the rate of disease progression and to slow cognitive and functional decline, which acts on the underlying pathology of Alzheimer’s disease.
The award for Clinical Advance of the Year recognizes the success of a new drug product in a clinical trial that is expected to lead to an advance in healthcare. It was awarded for the success of the Phase 3 Clarity AD study of lecanemab.
“It is a great honor to celebrate these prestigious acknowledgements together with our partner and to see how more than 20 years of research now is paying off,” says Gunilla Osswald BioArctic CEO. “It is exciting being part of the paradigm shift in the treatment of Alzheimer’s disease and bringing real hope to millions of patients affected.”
Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region and currently Eisai and BioArctic are preparing for a joint commercialization in the region.
Photo of Gunilla Osswald: BioArctic